Biogen (BIIB)
Company | Ticker | Sector | Industry | Quality | PAR |
---|---|---|---|---|
Biogen | BIIB | Healthcare | Drug Manufacturers - General | 28 | 1.9% |
Current Price ( 4/24 4:00PM EDT) | $201.99 | |||
CAPS Rating (Rate this stock on CAPS) | ||||
Expected Income Statement | ||||
Current Sales | 9,835.6 | |||
Sales Growth Forecast | -2.3% | |||
Net Profit Margin | 17.4% | |||
Projected Shares Outstanding | 130.03 | |||
EPS - Five year Forecast | $11.70 | |||
Average P/E Ratio | 19.0 | |||
Projected Average Price | $222.33 | |||
Price Appreciation (Annualized) | 1.9% | |||
Annual Dividend Yield | 0.0% | |||
Projected Annual Return | 1.9% | |||
Quality | ||||
Financial Strength | 63 | 15.7 | ||
EPS Stability | 45 | 11.2 | ||
Industry Sales Growth Rate | 4.0% | -7.3 | ||
Industry Net Profit Margin | 19.3% | 11.3 | ||
Calculated Quality Rating | 30.9 | |||
Fool CAPS | ||||
Total Players
950
Outperforms
76
Underperforms
All-Stars (186)
173
Outperforms (93%)
13
Underperforms
|
||||
Fundamental Data Updated: 12/29/2023 |